CYRX vs. IGMS, AUPH, ZNTL, IRWD, KROS, AMRX, AMPH, VERA, GERN, and RCKT
Should you be buying Cryoport stock or one of its competitors? The main competitors of Cryoport include IGM Biosciences (IGMS), Aurinia Pharmaceuticals (AUPH), Zentalis Pharmaceuticals (ZNTL), Ironwood Pharmaceuticals (IRWD), Keros Therapeutics (KROS), Amneal Pharmaceuticals (AMRX), Amphastar Pharmaceuticals (AMPH), Vera Therapeutics (VERA), Geron (GERN), and Rocket Pharmaceuticals (RCKT). These companies are all part of the "pharmaceutical preparations" industry.
IGM Biosciences (NASDAQ:IGMS) and Cryoport (NASDAQ:CYRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, community ranking, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.
42.8% of IGM Biosciences shares are owned by institutional investors. Comparatively, 92.9% of Cryoport shares are owned by institutional investors. 57.0% of IGM Biosciences shares are owned by company insiders. Comparatively, 10.1% of Cryoport shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
IGM Biosciences currently has a consensus price target of $17.89, suggesting a potential upside of 114.75%. Cryoport has a consensus price target of $18.25, suggesting a potential upside of 77.53%. Given Cryoport's stronger consensus rating and higher possible upside, research analysts plainly believe IGM Biosciences is more favorable than Cryoport.
Cryoport has higher revenue and earnings than IGM Biosciences. Cryoport is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks.
Cryoport received 175 more outperform votes than IGM Biosciences when rated by MarketBeat users. Likewise, 65.21% of users gave Cryoport an outperform vote while only 48.84% of users gave IGM Biosciences an outperform vote.
In the previous week, IGM Biosciences had 4 more articles in the media than Cryoport. MarketBeat recorded 6 mentions for IGM Biosciences and 2 mentions for Cryoport. IGM Biosciences' average media sentiment score of 0.74 beat Cryoport's score of 0.65 indicating that Cryoport is being referred to more favorably in the news media.
Cryoport has a net margin of -50.17% compared to Cryoport's net margin of -11,255.25%. IGM Biosciences' return on equity of -15.19% beat Cryoport's return on equity.
IGM Biosciences has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500. Comparatively, Cryoport has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500.
Summary
Cryoport beats IGM Biosciences on 11 of the 18 factors compared between the two stocks.
Get Cryoport News Delivered to You Automatically
Sign up to receive the latest news and ratings for CYRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CYRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cryoport Competitors List
Related Companies and Tools
